Trial reportBJU international2025
Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
Trial report in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesTo evaluate the rate of left-sided ureteroenteric strictures (UES) following robot-assisted radical cystectomy (RARC) with a retrosigmoid ileal conduit compared to a conventional ileal conduit in a randomised controlled trial (RCT). PATIENTS AND
methodsThis multicentre, RCT included 303 patients undergoing RARC between May 2020 and August 2022. Patients were randomised to receive either a retrosigmoid or a conventional ileal conduit. Analyses were performed an intention-to-treat basis.
resultsOf the 149 patients randomised for the retrosigmoid ileal conduit, a total of 137 (92%) patients received the allocated conduit. In the control group, 150 of 154 (97.4%) patients underwent RARC and one patient was lost to follow-up. At a median follow-up of 754 days, the rate of left-sided UES was 4.1% (six of 148) in the intervention group and 6.7% (10 of 149) in the control group (P = 0.31). No significant differences were observed in postoperative creatinine clearance or metabolic complications, including vitamin B
conclusionThe rate of left-sided UES was not significantly reduced with the retrosigmoid conduit compared to the conventional approach. However, the procedure was feasible without increased risk of metabolic complications and therefore may be a good alternative when extensive resection of the left ureter is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.